CFHR1 Specific Neutra™ Antibody Products

Struggling with challenges in therapeutic antibody development for complement-mediated diseases? Creative Biolabs' CFHR1 specific Neutra™ antibody products overcome obstacles in target specificity and functional validation through advanced hybridoma technology and rigorous epitope mapping, empowering precise modulation of CFHR1 activity to accelerate drug discovery.

Introduction to CFHR1

Complement factor H related 1 (CFHR1) is a member of the complement factor H (CFH) protein family, primarily expressed in the liver and secreted into plasma. It regulates complement activation by competing with CFH for binding to C3b and glycosaminoglycans, thereby modulating the alternative pathway. CFHR1's involvement in immune homeostasis makes it a pivotal therapeutic target for complement dysregulation disorders.

• Structural Features

CFHR1 consists of five short consensus repeat (SCR) domains, sharing homology with CFH but lacking C-terminal surface-binding regions. This structural divergence enables unique functional interactions with complement components. Its dimerization capability enhances avidity for ligands like C3b, making it a key player in controlling excessive complement activation on host cells.

• Related Signaling Pathways

CFHR1 intersects with the alternative complement pathway by inhibiting C3 convertase formation and stabilizing complement regulatory complexes. Dysregulation disrupts this balance, leading to uncontrolled inflammation and tissue damage. Additionally, CFHR1 interacts with thrombospondin-type domains in pathogens, influencing microbial immune evasion strategies.

Fig.1 Model of FHR1-induced inflammation.¹

• Associated Pathologies

CFHR1 genetic variations are linked to atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), and systemic lupus erythematosus (SLE). Autoantibodies against CFHR1 exacerbate complement activation in autoimmune conditions, highlighting its dual role as a therapeutic target and biomarker.

Applications of Anti-CFHR1 Neutralizing Antibodies

• Therapeutic Intervention in Complement Disorders

Anti-CFHR1 antibodies show promise in treating complement-driven pathologies. By neutralizing CFHR1-autoantibody complexes, they restore regulatory balance in autoimmune aHUS and SLE, reducing end-organ damage in preclinical studies, offering a targeted approach to inhibit uncontrolled complement activation while sparing systemic complement function.

• Diagnostic Biomarker Development

CFHR1 levels correlate with disease progression in AMD and SLE. Our antibodies enable quantitative assays for monitoring CFHR1 in serum, aiding in early diagnosis and personalized treatment strategies, allowing for more accurate disease staging and real-time assessment of therapeutic efficacy, crucial for improving long-term patient outcomes.

• Research Tools for Mechanistic Studies

These antibodies facilitate exploration of CFHR1's role in microbial pathogenesis. For instance, blocking CFHR1-pathogen interactions unveils novel therapeutic avenues for infections exploiting complement evasion, such as those caused by Neisseria meningitidis and other complement-evading bacteria.

Our Anti-CFHR1 Antibodies

Creative Biolabs' anti-CFHR1 neutralizing antibodies are meticulously validated for specificity and functional efficacy. These antibodies:

- Block pathogenic autoantibodies in autoimmune diseases by targeting CFHR1's functional epitopes.

- Inhibit complement overactivation in models of aHUS and AMD, preserving tissue integrity.

- Enable sensitive detection of CFHR1 in plasma and tissue samples via ELISA and immunohistochemistry.

Engineered for high affinity and low cross-reactivity, our antibodies support robust assay performance and translational research.

Creative Biolabs' CFHR1 specific Neutra™ antibodies deliver unmatched specificity and reliability for research and therapeutic development.

Contact our team to discuss your project requirements.

REFERENCE

1. Irmscher, Sarah, et al. "Factor H-related protein 1 (FHR-1) is associated with atherosclerotic cardiovascular disease." Scientific reports 11.1 (2021): 22511. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41598-021-02011-w